Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction on Wednesday, January 9th. The shares were sold at an average price of $296.20, for a total transaction of $977,460.00. Following the completion of the sale, the director now directly owns 333,279 shares in the company, valued at $98,717,239.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ ILMN opened at $307.07 on Friday. The firm has a market cap of $44.87 billion, a P/E ratio of 76.77, a P/E/G ratio of 1.99 and a beta of 1.11. Illumina, Inc. has a 12-month low of $207.51 and a 12-month high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. Illumina’s revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 earnings per share. Equities research analysts predict that Illumina, Inc. will post 5.76 earnings per share for the current fiscal year.
A number of research firms have recently commented on ILMN. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $347.00 price objective on the stock in a research note on Friday. ValuEngine lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their price objective for the company from $340.00 to $370.00 in a research note on Thursday, January 3rd. Barclays upped their price objective on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research note on Wednesday, October 24th. Finally, BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $340.40.
TRADEMARK VIOLATION NOTICE: This piece was reported by WKRB News and is the property of of WKRB News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.wkrb13.com/2019/01/12/illumina-inc-ilmn-director-sells-977460-00-in-stock.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: What is a Stop Order?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.